Primiano Christopher Brett 4
4 · Karyopharm Therapeutics Inc. · Filed Oct 14, 2020
Insider Transaction Report
Form 4
Primiano Christopher Brett
VP, Gen Counsel & Secretary
Transactions
- Sale
Common Stock
2020-10-13$17.20/sh−721$12,401→ 4,649 total - Sale
Common Stock
2020-10-13$16.85/sh−38,550$649,568→ 4,649 total - Exercise/Conversion
Common Stock
2020-10-13$10.39/sh+721$7,491→ 5,370 total - Exercise/Conversion
Stock Option (right to buy)
2020-10-13−38,550→ 64,250 totalExercise: $9.21Exp: 2029-02-14→ Common Stock (38,550 underlying) - Exercise/Conversion
Stock Option (right to buy)
2020-10-13−721→ 75,779 totalExercise: $10.39Exp: 2027-01-19→ Common Stock (721 underlying) - Exercise/Conversion
Common Stock
2020-10-13$9.21/sh+38,550$355,046→ 43,199 total
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- [F3]This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.